# ClinicalTrials.gov record NCT03548987

> PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03548987-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03548987-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03548987-semaglutide-v1.json
- Content SHA-256: `f822e38991c09ab07e6548eaa8e937161ec82df862dfc27209126a0c1f16d5e2`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03548987 ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

## Sources

<a id="source-ctg-observation-nct03548987-2022-01-19-39de46e416d0"></a>
- **ClinicalTrials.gov record NCT03548987 · retained source version 2022-01-19:39de46e416d0f24290e4628f67a36810b326ca7bc024dc15a5705017f17862d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03548987) (`ctg-observation-nct03548987-2022-01-19-39de46e416d0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03548987." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03548987-semaglutide-v1.json SHA-256: f822e38991c09ab07e6548eaa8e937161ec82df862dfc27209126a0c1f16d5e2.